AIMD
Ainos, Inc.2.1500
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
10.35MP/E (TTM)
-Basic EPS (TTM)
-3.92Dividend Yield
0%Recent Filings
8-K
Ainos launches SmellTech strategy
Ainos unveiled its long-term SmellTech platform strategy on January 5, 2026, to digitize smell for AI via proprietary AI Nose hardware and ScentAI's Smell Language Model. Hardware handles sensing and data generation; software focuses on AI models. In 2026, it shifts to scaled deployment in semiconductor manufacturing and robotics. Forward-looking plans carry execution risks.
8-K
Non-voting shares to subsidiary
Ainos issued 1,160,000 non-voting common shares to wholly owned subsidiary ScentAI on December 30, 2025, in exchange for 116,000,000 ScentAI shares. This internal restructuring leaves Ainos with 6,982,675 common shares outstanding. Issued under Section 4(a)(2) exemption. No voting dilution for public holders.
8-K
Q3 loss widens despite cuts
Ainos reported Q3 2025 results on November 13, showing $2,167 revenue, SG&A expenses down 22% year-over-year to $795K, and total operating expenses cut 8% to $2.8M—yet net loss widened to $2.9M amid heavy R&D. Cash dropped to $1.1M from $3.9M year-end. Annual meeting elected all seven directors with 98%+ support; stockholders approved auditor and 950K share reservation. Partnerships hit six; patents reached 123.
10-Q
Q3 FY2025 results
Ainos posted Q3 revenue of $2,167, up from nil y/y, with gross profit swinging to $1,690 from a $547 loss, yet operating loss narrowed just 8% y/y to $2.8M on $2.8M R&D and lighter SG&A. YTD revenue jumped 445% y/y to $113K from VELDONA Pet and NISD VOC sales, but operating loss widened 5% y/y to $9.7M while net loss held flat at $10.3M—EPS improved to $(2.61) from $(6.49) on 3.95M diluted shares (anti-dilution from warrants/notes excluded). Cash burned to $1.1M amid $3.8M operating outflow, offset by $853K ATM proceeds; $11M related-party convertible notes loom at 6%. Cash is tight. Foreign exchange swings threaten Taiwan revenue.
IPO
Website
Employees
Sector
Industry
AEMD
Aethlon Medical, Inc.
2.94-0.11
AMIX
Autonomix Medical, Inc.
0.63-0.03
AVNS
Avanos Medical, Inc.
11.62-0.24
AXIM
Axim Biotechnologies, Inc.
0.02+0.00
INBS
Intelligent Bio Solutions Inc.
5.50+0.00
IRME
IR-Med Inc.
0.02-0.01
MDAI
Spectral AI, Inc.
1.50+0.01
PMEDF
PREDICTMEDIX AI INC.
0.05-0.00
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
ZOMDF
Zomedica Corp.
0.11+0.00